Bristol-Myers Squibb commences tender offer to acquire Medarex

Posted on: Tue, 28 Jul 2009 14:21:00 EDT


Symbols: BMY, MEDX
Jul 28, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
MEDX | Quote | Chart | News | PowerRating -- Update on July 28, 2009:

Bristol-Myers Squibb Company (BMS), through its wholly-owned subsidiary Puma Acquisition Corporation, has commenced a cash tender offer to acquire all of the outstanding shares of Medarex, Inc. Both the companies are based in the US.

BMS is a pharmaceuticals company focused on cancer, cardiovascular, immunoscience, infectious diseases, and psychiatric disorders, while Medarex is a biopharmaceutical company focused on cancer, inflammation, and autoimmune disorders.

The tender offer is scheduled to expire on August 24, 2009, unless extended.

Announcement (July 22, 2009):

BMS has signed a definitive agreement to acquire all of the outstanding shares of Medarex at a price of $16 per share in cash. The transaction is valued at approximately $2,400 million.

The offer price represents a premium of 90% to Medarex's closing share price on July 21, 2009. The Board of Directors of both the companies have approved the transaction. The tender offer would expect to close in approximately 30 days after commencement of the tender offer.

JPMorgan Securities, Inc. is acting as financial advisor and Cravath, Swaine & Moore LLP is acting as legal advisor to BMS. Goldman, Sachs & Co. is acting as financial advisor and Covington & Burling LLP is acting as legal advisor to Medarex. Georgeson, Inc. is acting as information agent for BMS.

Deal Value (US$ Million) 2400
Deal Type Acquisition
Sub-Category 100% Acquisition
Deal Status Announced: 2009-07-22

Deal Participants

Target (Company)   Medarex, Inc.
Acquirer (Company) Bristol-Myers Squibb Company

Deal Rationale

The addition of Medarex's technology platform and pipeline would allow BMS to strengthen its position in biologics, specifically in immuno-oncology.

BMS would gain access to Medarex's ultimAb human antibody development system, antibody-drug conjugate (ADC) technology, rights to seven antibodies in clinical trials under Medarex's sole sponsorship and three other antibodies being co-developed with other partners. In addition, BMS gains full ownership and rights to ipilimumab.

Bid Premium ($ per share) 90

For full details on Bristol-Myers Squibb Co (BMY) BMY. Bristol-Myers Squibb Co (BMY) has Short Term PowerRatings at TradingMarkets. Details on Bristol-Myers Squibb Co (BMY) Short Term PowerRatings is available at This Link.

For full details on (MEDX) MEDX. (MEDX) has Short Term PowerRatings at TradingMarkets. Details on (MEDX) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.